Sign in
Taking people in United StatesPhase 2

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Key facts

Who runs it
Frantz Viral Therapeutics, LLC
Where
Cleveland, Fort Myers, Indianapolis, and Mayfield Heights, United StatesSee the 5 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
27 people, planned
Started
6 Dec 2023
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Artesunate ointment
  • Placebo ointment
Record updated
14 August 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adult women age ≥ 18 years
  • Capable of informed consent
  • Able to collaborate with planned follow-up (transportation, compliance history, etc)
  • Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry
  • Positive HPV test at study entry (any genotype)
  • Women of childbearing potential agree to use birth control during the dosing phase (through week 8)
  • Laboratory values at Screening of:; Serum alanine transaminase (SGPT/ALT) < 5 x upper limit of normal (ULN); Serum aspartate transaminase (SGOT/AST) < 5 x ULN; Serum Bilirubin (total) < 2.5 x ULN; Serum Creatinine ≤ 1.5 x ULN
  • Weight ≥ 50kg

Who cannot take part

  • Concurrent anal, vulvar, or cervical cancer
  • Currently receiving systemic chemotherapy or radiation therapy for another cancer
  • Concomitant use of Efavirenz for HIV antiretroviral treatment
  • Concomitant use of strong UGT inhibitors
  • Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study
  • Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy)
  • Concurrent treatment with systemic corticosteroids
  • Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen
  • HIV-positive participants with a CD4 count < 200
  • Pregnant and nursing women
  • Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry

This trial is currently available in United States.

  • Cleveland Clinic Fairview HospitalCleveland, United StatesContact: Donna WhiteTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Donna WhiteTaking people
  • Florida Gynecologic OncologyFort Myers, United StatesContact: Edward C. Grendys, MD FACOG, FACSTaking people
  • Ascension St. VincentIndianapolis, United StatesContact: Sarah Goodrich, MDTaking people
  • Hillcrest HospitalMayfield Heights, United StatesContact: Donna WhiteTaking people

About the trial

What the trial wants to find out

This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).

The 2 groups in the trial

  • Artesunate ointmentExisting treatment, for comparison

    Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks

  • Placebo ointmentPlacebo, for comparison

    Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
Record updated
14 August 2025